AGENDA ITEM

Wednesday, June 24

9:00 Welcome & Introductions

9:15 Meningococcal
   Introduction
   Safety and immunogenicity of MenACYW-TT
   MenACYW-TT: GRADE and EtR
   Workgroup considerations

10:00 Influenza Vaccines
   Introduction
   WG Considerations and proposed recommendations

11:00 Public Comment

11:15 Break

11:45 VOTES
   Influenza Vaccines
   VFC Vote
   Meningococcal

12:00 Lunch

12:30 Coronavirus Disease 2019 (COVID-19)
   Epidemiology of COVID-19
   COVID-19 vaccine products in development

2:30 Break

2:45 Coronavirus Disease 2019 (COVID-19) Continued
   Safety and immunogenicity of COVID-19 vaccine candidates
   Work group considerations and next steps
   Impact of COVID-19 pandemic on routine pediatric vaccination services

4:45 Agency Updates
   CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, OIDP

5:00 Adjourn

Acronyms

CDC        Centers for Disease Control & Prevention
CMS        Centers for Medicare and Medicaid Services
DoD        Department of Defense
DVA        Department of Veterans Affairs
EtR        Evidence to Recommendations Framework
FDA        Food and Drug Administration
GRADE      Grading of Recommendations Assessment, Development and Evaluation
HRSA       Health Resources and Services Administration
IHS        Indian Health Service
NCHHSTP    National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD      National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID     National Center for Emerging and Zoonotic Diseases [of CDC/OID]
OIDP       Office of Infectious Disease and HIV/AIDS Policy
PrEP       Pre-exposure Prophylaxis
SAGE       Strategic Advisory Group of Experts
WG         Work Group
WHO        World Health Organization
VE         Vaccine Effectiveness